Bcl-2 expression as a predictor of chemosensitivities and survival in small cell lung cancer

Cancer Journal from Scientific American

Volumn 2, Issue 4, 1996, Pages 212-216

  Takayama, Koichi ^a   Ogata, Kenichi ^a   Nakanishi, Yoichi ^a   Yatsunami, Jun ^a   Kawasaki, Masayuki ^a   Hara, Nobuyuki ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Bcl 2 gene; Chemosensitivity; Immunostaining; Small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN BCL 2;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; DRUG RESISTANCE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; SMALL CELL CARCINOMA; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE;

EID: 0000305464     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Minna JD. The molecular biology of lung cancer pathogenesis. Chest 1993;103:449S-456S.
2. Yokota A, Wada M, Shimosato Y, Terada M, Sugimura T. Loss of heterozygosity on chromosome 3, 13, 17 in small cell carcinoma and on chromosome 3 in adenocarcinoma of the lung. Proc Natl Acad Sci USA 1987;84:9252-9256.
3. D'Amico D, Carbone D, Mitsudomi T et al. High frequency of somatically acquired p53 mutations in small cell lung cancer cell lines and tumors. Oncogene 1991;7:339-346.
4. Mori N, Yokota J, Akiyama T et al. Variable mutations of RB gene in small cell lung carcinoma. Oncogene 1990;5:1713-1717.
5. Johnson BE, Ihde DC, Makuch R et al. myc family oncogene amplification in tumor cell line established from small cell lung cancer patients and its relationship to clinical status and cause. J Clin Invest 1987;79:1629-1634.
6. Takahashi T, Obata Y, Sekido Y et al. Expression and amplification of myc gene family in small cell lung cancer and its relation to biological characteristics. Cancer Res 1989;49:2683-2688.
7. Korsmeyer SJ. Bcl-2 initiates a new category of oncogene: regulator of cell death. Blood 1992;80:879-886.
8. Lotem J, Sachs L. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ 1993;4:41-47.
9. Miyashita T, Reed JC. bcl-2 gene transfer increases relative resistance of S 49.1 and WEHI 7.2 lymphoid cells to cell death DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 1992;52:5407-5411.
10. Ikegami N, Katsumata M, Minna J, Tsujimoto Y. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 1994;54:6-8.
11. Shin RW, Iwaki T, Kitamura T, Tateishi J. Hydrate autoclave pretreatment enhances TAU immunoreactivity in formalin-fixed normal and Alzheimer disease tissue. Lab Invest 1991;64:693-702.
12. Ihde DC. Current status of therapy for small cell carcinoma of the lung. Cancer 1984;54:2722-2728.
13. Albain KS, Crowley JC, LeBlanc M, Livingston RB. Determinants of survival outcome in small-cell lung cancer: an analysis of the 2,580 patients. Southwest Oncology Group data base. J Clin Oncol 1990;8:1563-1574.
14. Lowe SW, Ruley HE, Jacks T, Housmann DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-967.
15. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang W, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of wildtype p53 gene. Cancer Res 1994;54:2287-2291.
16. Lowe SW, Bodies S, Mcclatohey A et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:804-810.
17. Brown R, Clugston C, Burns P et al. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 1993;55:678-684.
18. Lee JM, Bernstein A. p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 1993;90:5742-5746.
19. Prezzella F, Turley H, Kazu I et al. bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993;329:690-694.
20. Chan HSL, Haddad G, Thorner PS et al. P-glycoprotein expression as a predictor of outcome of therapy for neuroblastoma. N Engl J Med 1991;325:1608-1614.
21. Holzmayer TA, Hilsenbeck S, Von Hoff DD. Clinical correlates of MDR 1 (p-glycoprotein) gene expression in ovarian and small-cell lung carcinoma. J Natl Cancer Intr 1992;84:1486-1491.
22. Satta T, Isobe K, Yamauchi M, Nakashima I, Takagi H. Expression of mdr 1 and glutathione S-transferase genes and chemosensitivities in human gastrointestinal cancer. Cancer 1992;69:941-946.
23. Keith WN, Stallard S, Brown R Expression of mdr 1 and GST in human breast tumors: comparison to in vivo chemosensitivity. Br J Cancer 1990;61:712-716.
24. Tsai C-M, Chang K-T, Perng R-P et al. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst 1993;55:678-684.